Discounted Cash Flow Rating
Strong Sell
Return on Equity Rating
Strong Sell
Debt to Equity Rating
Strong Buy
Price to Earnings Rating
Strong Buy
Analyst Rating
Neutral
Simple Moving Average
Neutral
Exponential Moving Average
Neutral
Relative Strength Index
Buy
Standard Deviation
Strong Sell
Williams %R
Strong Buy
Average Directional Index
Strong Sell
Insider Trading
Strong Buy
Wall Street Data Solutions Rating
Neutral
B
Celularity Inc. Warrant (CELUW)
Pharmaceutical Preparations
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
170 PARK AVE
FLORHAM PARK, NJ
Current Price
---.--
% Change Today
0.00%
Change Amt. Today
0.00
Active Status
Active
Listing Date
07/19/2021
Market Cap
64,854,611
Shares Outstanding
193,660,000
Weighted SO
N/A
Total Employees
N/A
Upcoming Earnings
N/A
Similar Tickers
Beta
0.4440
Last Div
0.0000
Range
0.0185-0.0185
Chg
-0.0015
Avg Vol
N/A
Mkt Cap
64854611
Exch
NASDAQ
Country
US
Phone
908 768 2170
DCF Diff
8.5654
DCF
-3.5454
Div Yield
0.0000
P/S
2.9447
EV Multiple
-1.7798
P/FV
1.4430
Div Yield %
0.0000
P/E
-0.3004
PEG
-0.0431
Payout
0.0000
Current Ratio
0.2941
Quick Ratio
0.2086
Cash Ratio
0.0034
DSO
194.2414
DIO
52.5829
Op Cycle
246.8242
DPO
129.2773
CCC
117.5469
Gross Margin
-0.7537
Op Margin
-8.4444
Pretax Margin
-8.6200
Net Margin
-8.6390
Eff Tax Rate
0.0033
ROA
-1.3672
ROE
-2.2786
ROCE
-2.5106
NI/EBT
1.0022
EBT/EBIT
1.0208
EBIT/Rev
-8.4444
Debt Ratio
0.4546
D/E
1.5971
LT Debt/Cap
0.3899
Total Debt/Cap
0.6150
Int Coverage
-63.7768
CF/Debt
-0.5914
Equity Multi
3.5129
Rec Turnover
1.8791
Pay Turnover
2.8234
Inv Turnover
6.9414
FA Turnover
0.2889
Asset Turnover
0.1583
OCF/Share
-1.9963
FCF/Share
-2.2052
Cash/Share
0.0117
OCF/Sales
-1.6989
FCF/OCF
1.1046
CF Coverage
-0.5914
ST Coverage
-0.9859
CapEx Coverage
-9.5566
Div&CapEx Cov
-9.5566
P/BV
1.4430
P/B
1.4430
P/S
2.9447
P/E
-0.3004
P/FCF
-1.5691
P/OCF
-1.5278
P/CF
-1.5278
PEG
-0.0431
P/S
2.9447
EV Multiple
-1.7798
P/FV
1.4430
DPS
0.0000
Latest Headlines (EST)
Revenue Product Segmentation
Year | Purchases | Sales | Total Bought | Total Sold |
---|
Transaction Date | Name | Type Of Owner | Price | Securities Owned | Securities Transacted | Security Name | Transaction Type |
---|
Less Than 3 Months
0.00 Shares Bought (0 %)
0.00 Shares Sold (0%)
3 - 6 Months
49.79M Shares Bought (88.41 %)
6.53M Shares Sold (11.59%)
6 - 9 Months
9.36M Shares Bought (59.74 %)
6.31M Shares Sold (40.26%)
9 - 12 Months
11.19M Shares Bought (55.25 %)
9.06M Shares Sold (44.75 %)
Investor Name | Investment Discretion | Type of Security | Shares Owned | Avg Price Paid | Market Value | Change In Market Value | Change In Market Value (%) | Ownership | Weight |
---|
Date | Investors Holding | Closed Positions | Increased Positions | Reduced Positions | New Positions | Total Invested | Put/Call Ratio | Total Calls | Total Puts |
---|
Owner | Shares Owned |
---|
2020 | 2021 | 2022 | 2023 | 2024 | 1970 | 1970 | |
---|---|---|---|---|---|---|---|
Revenue | 0.00 | ▲ 3.24M | ▲ 4.86M | ▼ 4.13M | ▼ 3.79M | ▼ | |
Cost Of Revenue | 564.34K | ▲ 1.17M | ▲ 4.66M | ▲ 5.25M | ▼ 3.60M | ▼ | |
Gross Profit | -564.34K | ▲ 2.07M | ▼ 197.00K | ▼ -1.12M | ▲ 184.00K | ▼ | |
Gross Profit Ratio | 0.00 | ▲ 0.64 | ▼ 0.04 | ▼ -0.27 | ▲ 0.05 | ▼ | |
Research And Development Expenses | 0.00 | ▲ 13.92M | ▲ 24.69M | ▼ 10.99M | ▼ 5.18M | ▼ | |
General And Administrative Expenses | 246.96K | ▼ 241.64K | ▼ 0.00 | ▲ 18.92M | ▼ 0.00 | ||
Selling And Marketing Expenses | 0.00 | ▲ 5.73M | ▼ 0.00 | ▲ 163.00K | ▼ 0.00 | ||
Selling General And Administrative Expenses | 246.96K | ▲ 5.97M | ▲ 13.21M | ▲ 19.08M | ▼ 10.75M | ▼ | |
Other Expenses | 0.00 | ▼ -3.00K | ▲ 34.43M | ▼ 553.00K | ▲ 1.14M | ▼ | |
Operating Expenses | 246.96K | ▲ 20.45M | ▲ 37.90M | ▼ 30.62M | ▼ 16.73M | ▼ | |
Cost And Expenses | 246.96K | ▲ 21.62M | ▲ 42.56M | ▼ 35.87M | ▼ 20.33M | ▼ | |
Interest Income | 0.00 | ▲ 134.00K | ▼ 8.00K | ▲ 210.00K | ▼ 23.00K | ▼ | |
Interest Expense | -1.21M | ▲ 724.00K | ▲ 759.00K | ▼ -59.72M | ▲ 971.00K | ▼ | |
Depreciation And Amortization | 1.21M | ▲ 1.83M | ▲ 2.61M | ▼ -50.32M | ▲ 2.34M | ▼ | |
Ebitda | 958.79K | ▼ -16.41M | ▲ -3.26M | ▼ -32.84M | ▲ -13.04M | ▼ | |
Ebitda Ratio | 0.00 | ▼ -5.06 | ▲ -0.67 | ▼ -7.95 | ▲ -3.44 | ▼ | |
Operating Income | -246.96K | ▲ 11.06M | ▼ -14.95M | ▲ 17.49M | ▼ -99.26M | ▼ | |
Operating Income Ratio | 0.00 | ▲ 3.41 | ▼ -3.08 | ▲ 4.23 | ▼ -26.22 | ▼ | |
Total Other Income Expenses Net | 1.21M | ▲ 22.81M | ▲ 34.43M | ▼ 6.96M | ▼ -76.39M | ▼ | |
Income Before Tax | 958.79K | ▲ 3.84M | ▼ -4.02M | ▲ 24.45M | ▼ -93.88M | ▼ | |
Income Before Tax Ratio | 0.00 | ▲ 1.18 | ▼ -0.83 | ▲ 5.92 | ▼ -24.80 | ▼ | |
Income Tax Expense | 201.52K | ▼ -69.00K | ▲ 20.00K | ▼ 13.00K | ▲ 2.11M | ▼ | |
Net Income | 757.27K | ▲ 3.91M | ▼ -4.04M | ▲ 24.43M | ▼ -93.88M | ▼ | |
Net Income Ratio | 0.00 | ▲ 1.21 | ▼ -0.83 | ▲ 5.92 | ▼ -24.80 | ▼ | |
Eps | 0.09 | ▼ 0.03 | ▼ -0.03 | ▲ 1.64 | ▼ -4.98 | ▼ | |
Eps Diluted | 0.09 | ▼ 0.03 | ▼ -0.03 | ▲ 0.16 | ▼ -4.98 | ▼ | |
Weighted Average Shs Out | 8.65M | ▲ 122.49M | ▲ 124.12M | ▼ 14.89M | ▲ 18.83M | ▼ | |
Weighted Average Shs Out Dil | 8.65M | ▲ 122.49M | ▲ 124.31M | ▼ 14.89M | ▲ 18.83M | ▼ |